NZ503248A - Solid oral dosage form comprising a combination of metformin and glibenclamide - Google Patents

Solid oral dosage form comprising a combination of metformin and glibenclamide

Info

Publication number
NZ503248A
NZ503248A NZ503248A NZ50324899A NZ503248A NZ 503248 A NZ503248 A NZ 503248A NZ 503248 A NZ503248 A NZ 503248A NZ 50324899 A NZ50324899 A NZ 50324899A NZ 503248 A NZ503248 A NZ 503248A
Authority
NZ
New Zealand
Prior art keywords
glibenclamide
metformin
combination
dosage form
oral dosage
Prior art date
Application number
NZ503248A
Other languages
English (en)
Inventor
Yves Bonhomme
Geoffrey Nicholson
Gillian Cave
Sarah J Nicholson
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8235441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ503248(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipha filed Critical Lipha
Publication of NZ503248A publication Critical patent/NZ503248A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ503248A 1998-07-15 1999-07-12 Solid oral dosage form comprising a combination of metformin and glibenclamide NZ503248A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401781A EP0974356B1 (en) 1998-07-15 1998-07-15 Tablets comprising a combination of metformin and glibenclamide
PCT/EP1999/005571 WO2000003742A2 (en) 1998-07-15 1999-07-12 Solid oral dosage form comprising a combination of metformin and glibenclamide

Publications (1)

Publication Number Publication Date
NZ503248A true NZ503248A (en) 2002-09-27

Family

ID=8235441

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ503248A NZ503248A (en) 1998-07-15 1999-07-12 Solid oral dosage form comprising a combination of metformin and glibenclamide

Country Status (27)

Country Link
US (2) US6303146B1 (enExample)
EP (4) EP0974356B1 (enExample)
JP (2) JP2002520371A (enExample)
KR (2) KR20040053177A (enExample)
CN (2) CN1486698A (enExample)
AP (1) AP1450A (enExample)
AR (2) AR013052A1 (enExample)
AT (1) ATE250418T1 (enExample)
AU (2) AU753604B2 (enExample)
BR (1) BR9906600A (enExample)
CA (1) CA2303537C (enExample)
DE (1) DE69818444T2 (enExample)
DK (1) DK0974356T3 (enExample)
DZ (1) DZ2846A1 (enExample)
ES (1) ES2206868T3 (enExample)
ID (1) ID25784A (enExample)
MA (1) MA24930A1 (enExample)
MY (1) MY129552A (enExample)
NZ (1) NZ503248A (enExample)
OA (1) OA11400A (enExample)
PT (1) PT974356E (enExample)
RU (2) RU2226396C2 (enExample)
SI (1) SI0974356T1 (enExample)
TW (2) TWI245632B (enExample)
UY (1) UY25611A1 (enExample)
WO (1) WO2000003742A2 (enExample)
ZA (1) ZA200001159B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
IL149139A0 (en) * 1999-11-03 2002-11-10 Bristol Myers Squibb Co Pharmaceutical compositions containing metformin and glyburide
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2816841B1 (fr) * 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
EP1738751B1 (en) * 2001-01-12 2011-05-11 Sun Pharma Advanced Research Company Ltd Spaced drug delivery system
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
CN1270724C (zh) * 2001-07-30 2006-08-23 三菱制药株式会社 餐后高血糖改善剂
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
US9045438B2 (en) * 2002-01-25 2015-06-02 Silanes S.A. De C.V. Pharmaceutical composition containing glimepiride and metformin hydrochloride
ATE536173T1 (de) * 2002-02-21 2011-12-15 Biovail Lab Int Srl Formulierungen mit modifizierter freisetzung von mindestens einer form von tramadol
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
CA2480824A1 (fr) 2002-04-09 2003-10-16 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
EP1562607A1 (en) * 2002-11-15 2005-08-17 Ranbaxy Laboratories, Ltd. Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation
CN1780642A (zh) * 2003-04-15 2006-05-31 中外制药株式会社 糖尿病治疗剂
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
PE20061245A1 (es) * 2005-03-30 2007-01-06 Generex Pharm Inc Composiciones para la transmision transmucosa oral de la metformina
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
WO2008062273A2 (en) * 2006-11-20 2008-05-29 Cadila Pharmaceuticals Limited Solid oral dosage form having antidiabetic drug combination
JO3272B1 (ar) 2007-07-19 2018-09-16 Takeda Pharmaceuticals Co مستحضر صلب يشمل ألوجليبتين وميتفورمين هيدروكلوريد
NZ597885A (en) 2007-07-26 2013-08-30 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
WO2011135106A1 (es) * 2010-04-26 2011-11-03 Smart Pharma Solutions, S.L Granulado altamente dispersable para la preparación de formulaciones de sustancias activas de altas dosis y procedimiento de obtención del mismo
RU2451506C1 (ru) 2011-06-02 2012-05-27 Сергей Юрьевич Лешков Комбинация для лечения сахарного диабета и его осложнений
WO2013086443A1 (en) 2011-12-08 2013-06-13 Amgen Inc. Agonistic human lcat antigen binding proteins and their use in therapy
EP2790729A4 (en) * 2011-12-12 2015-08-12 Orbis Biosciences Inc PARTICULATE FORMULATIONS WITH DELAYED RELEASE
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
CN105030793A (zh) * 2015-08-25 2015-11-11 瑞阳制药有限公司 二甲双胍格列本脲胶囊及其制备方法
WO2019070109A1 (es) * 2017-10-03 2019-04-11 Infinite Clinical Research International, S.A. De C.V. Triconjugado para el tratamiento de diabetes mellitus
CN115315426B (zh) 2020-04-01 2023-12-12 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
EP4130005A4 (en) 2020-04-01 2024-04-24 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF
KR102484756B1 (ko) * 2020-11-13 2023-01-06 한국생산기술연구원 용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362704C (de) * 1921-08-09 1922-11-02 Naamlooze Vennootschap Interna Vorrichtung zum Senken einer Last, insbesondere eines Rettungsbootes
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
IE63463B1 (en) * 1989-02-06 1995-04-19 Zeneca Ltd Phenylsulphone derivatives
GB9016978D0 (en) * 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
AU8539398A (en) 1997-06-18 1999-01-04 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and metformin
US6544564B1 (en) * 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition

Also Published As

Publication number Publication date
WO2000003742A3 (en) 2000-04-20
ID25784A (id) 2000-11-02
KR20040053177A (ko) 2004-06-23
AU2003261560A1 (en) 2005-05-26
TW200303208A (en) 2003-09-01
EP2269613A2 (en) 2011-01-05
DE69818444D1 (de) 2003-10-30
CA2303537C (en) 2005-12-06
RU2003126257A (ru) 2005-02-27
CA2303537A1 (en) 2000-01-27
UY25611A1 (es) 2000-08-21
DK0974356T3 (da) 2003-10-27
CN1146427C (zh) 2004-04-21
EP1011684A2 (en) 2000-06-28
USRE38629E1 (en) 2004-10-19
AR065970A2 (es) 2009-07-15
EP0974356B1 (en) 2003-09-24
EP1435240A3 (en) 2009-08-12
JP2002520371A (ja) 2002-07-09
US6303146B1 (en) 2001-10-16
MY129552A (en) 2007-04-30
CN1275082A (zh) 2000-11-29
JP2003292443A (ja) 2003-10-15
AU753604B2 (en) 2002-10-24
DZ2846A1 (fr) 2003-12-01
ES2206868T3 (es) 2004-05-16
TW555560B (en) 2003-10-01
EP1435240A2 (en) 2004-07-07
BR9906600A (pt) 2000-07-18
KR20010030603A (ko) 2001-04-16
AP2000001757A0 (en) 2000-03-31
TWI245632B (en) 2005-12-21
KR100478347B1 (ko) 2005-03-23
AR013052A1 (es) 2000-11-22
SI0974356T1 (en) 2003-12-31
CN1486698A (zh) 2004-04-07
MA24930A1 (fr) 2000-04-01
PT974356E (pt) 2004-02-27
RU2286788C2 (ru) 2006-11-10
ATE250418T1 (de) 2003-10-15
AU5417999A (en) 2000-02-07
ZA200001159B (en) 2001-05-31
WO2000003742A2 (en) 2000-01-27
AP1450A (en) 2005-07-25
EP2269613A3 (en) 2012-10-17
RU2226396C2 (ru) 2004-04-10
DE69818444T2 (de) 2004-05-06
EP0974356A1 (en) 2000-01-26
OA11400A (en) 2004-04-08

Similar Documents

Publication Publication Date Title
NZ503248A (en) Solid oral dosage form comprising a combination of metformin and glibenclamide
MX9602176A (es) Modafinilo teniendo tamaño de particulas definido.
IL106353A0 (en) Unsymmetrical mono-3-nitro-bis-naphthalimides,their preparation and pharmaceutical compositions containing them
EP0661311A3 (en) Fine particles from the combination of film-forming compositions.
DE3265618D1 (en) Prolonged-action multiple-layer tablets
IL114622A0 (en) Heteroaryl-oxazolidinones and pharmaceutical compositions containing them
HUP9800792A3 (en) Benzylpiperidines and piperazines, their use and pharmaceutical compositions containing the same
BG98933A (en) Cooled and atomized nabumetone
GB9116472D0 (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein
GR3007981T3 (enExample)
MY106371A (en) Oral pharmaceutical compositions in unit dosage form
EP0640350A3 (en) Ceramic particles and their preparation.
ZA942577B (en) 5-acylamino-1,2,4-thiadiazoles their preparation and pharmaceutical compositions containing them
IL110809A0 (en) 1,5-diphenyl-3-pyrazolylalkyl-n-hydroxydithiocarbamates and pharmaceutical compositions containing them
NZ208669A (en) Human calcitonin 2, and pharmaceutical compositions
NZ221189A (en) 1,4-benzodiazepines and pharmaceutical compositions
MD970269A (en) Clavulanates
IL111692A0 (en) Quinoxalines and pharmaceutical compositions containing them
NZ219719A (en) Endo-4-amino-5-chloro-2-methoxy-n-cl-azabicyclo -(3,3,1)-non-4-yl)-benzamide and pharmaceutical compositions
IL101482A0 (en) Substituted 2',3'-dideoxy-5-trifluoromethyluridines,and pharmaceutical compositions containing them
BR9915172A (pt) Recipiente para alimentos tendo superfìcie resistente a corte.
IL115882A0 (en) Oxazolyl-and thiazolylimidazo-benzo-and thienodiazepines their manufacture and pharmaceutical compositions containing them
IL114161A0 (en) Amido- quinoxalinediones pharmaceutical compositions containing them and their use
IL94658A0 (en) 1,5-diazabicyclodiones and pharmaceutical compositions containing them
SG25394G (en) Sustained release pharmaceutical compositions and the preparation of particles for use therein.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired